Based on these mechanisms, targeting the SphK1/S1P/S1PR2 axis could not only suppress tumor proliferation and angiogenesis but also reverse EMT phenotypes and resistance, providing promising intervention strategies for precise HCC treatment. This evidence concerns the gene SPHK1 and hepatocellular carcinoma.